Bioxcel therapeutics announces first patient dosed in tranquility ii phase 3 trial for acute treatment of agitation in patients with alzheimer's disease

Top-line data for tranquility ii anticipated in q4 2022/early q1 2023

BTAI Ratings Summary

BTAI Quant Ranking